Keywords: NeRRe Therapeutics, New company, GlaxoSmithKline, Novo, GlycoVaxyn, collaboration, Bacterial vaccines
NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK
Article | 20 December 2012
NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists (NRAs) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
